Press Releases – Global Alzheimer’s Platform Foundation

Global Alzheimer’s Platform Foundation Statement on Biogen’s Submission of Aducanumab Application to the FDA

Posted on July 9, 2020 by Taylor Disselhorst

Washington D.C. (July 9, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding Biogen’s submission of its BLA application for Aducanumab with the FDA: “The Alzheimer’s research community is looking forward to a thoughtful review of Aducanumab and ideally, approval by the FDA. This application represents a singular […]

GAP Statement on Racial Inequality

Posted on June 2, 2020 by Taylor Disselhorst

June 2, 2020 The events that spurred the reaction around the country this weekend are painful reminders that injustice remains in our world. At the Global Alzheimer’s Platform Foundation® (GAP), we agree that monumental changes on local and national levels are necessary to address the issues plaguing Black and African American people in our country […]

Investors Meet Opportunity at Inaugural Global Alzheimer’s Platform Foundation Innovation Summit

Posted on February 26, 2020 by Taylor Disselhorst

At a pivotal time in Alzheimer’s research, the GAP Foundation and the Alzheimer’s Drug Discovery Foundation will connect funders with leading innovators Updated on March 26, 2020: The Global Alzheimer’s Platform Foundation (GAP) has announced it is postponing the GAP Innovation Summit that was to be held on May 5, 2020 with our partner, the […]

Citizen Scientists Move Researchers Closer to Alzheimer’s Cure

Posted on October 23, 2019 by GAP

Three research volunteers given first ever national award for their essential role in combatting the greatest public health crisis for our society in this century Washington, DC (October 23, 2019) – Today, the Global Alzheimer’s Platform Foundation® (GAP) honors three Citizen Scientists® in recognition of the indispensable role clinical trial volunteers play in the fight […]

Global Alzheimer’s Platform Foundation Commends Biogen and Eisai On Positive Aducanumab Findings

Posted on October 22, 2019 by GAP

First disease-modifying drug in 16 years to be submitted for FDA approval in 2020 ***John Dwyer is available for comment today live from the National Alzheimer’s Summit in Washington, D.C.*** Washington, DC (October 22, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement on the announcement today […]

Spartan Bioscience Partners with the Global Alzheimer’s Platform Foundation to Accelerate Alzheimer’s Research

Posted on July 31, 2019 by GAP

Spartan will donate $5 to the GAP Transportation Program from each sale of its rapid APOE test to GAP-Net Research Sites Ottawa, Canada (July 31, 2019) – Spartan Bioscience today announced a partnership with the Global Alzheimer’s Platform Foundation® (GAP) to help recruit possible study participants and accelerate Alzheimer’s clinical trials. Through the partnership, Spartan will donate $5 from […]

Global Alzheimer’s Platform Foundation Honors More Than 100 Clinical Trial Participants During National Citizen Scientist Week.

Posted on June 17, 2019 by GAP

During National Citizen Scientist Week, June 17-21, GAP Honors More Than 100 Award Nominees Washington, DC (June 17, 2019) – June 17-21, 2019 is the first ever National Citizen Scientist Week, a time to honor people who volunteer for Alzheimer’s research and inspire hope for new therapies for the disease. To celebrate the contributions of the remarkable volunteers […]

Global Alzheimer’s Platform Foundation Commends National Institute on Aging for Advancing Its 2025 Goal by Funding a Diversified Portfolio of Studies

Posted on May 20, 2019 by GAP

NIA Makes $9 Million Multiyear Grant to Study New Therapeutic Approach, an Orally- Administered Treatment for Alzheimer’s Washington, DC (May 20, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, today issued the following statement: “The nearly six million Americans with Alzheimer’s and their families deserve for no scientific stone to go […]

Global Alzheimer’s Platform Foundation Commends Commissioner Seema Verma and CMS for New Medicare Advantage Benefits and Payment Policies That Will Improve the Care Of Beneficiaries At Risk For Alzheimer’s and Related Dementias

Posted on April 10, 2019 by GAP

Washington, DC (April 10, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, today issued the following statement: “The Global Alzheimer’s Platform Foundation thanks Commissioner Seema Verma and the Centers for Medicare and Medicaid Services (CMS) for its thoughtful and impactful leadership in implementing policies that will improve Medicare Advantage beneficiaries’ ability […]

GAP Foundation Unveils Roadmap for Increasing Participation in Alzheimer’s Research

Posted on February 28, 2019 by GAP

GAP President Calls Memory Fitness Programs Through Medicare Advantage “a Game-Changer” Nashville (February 28, 2019)? – Global Alzheimer’s Platform Foundation (GAP) President John Dwyer today announced a roadmap for increasing participation in Alzheimer’s clinical trials by supporting and collaborating with memory fitness supplemental benefit programs offered through select Medicare Advantage plans across the United States. Dwyer […]